• Patients
  • HC Professionals
  • Investors
  • Media
Join us
  • Atopic dermatitis
  • Psoriasis
  • Actinic keratosis
  • Acne
    • Onychomycosis
    • Alopecia areata
    • Keratinocyte cancer
    • Vitiligo
    • Hidradenitis suppurativa
    • Rare skin diseases
Go to Dermatology
  • Dermatology
  • Atopic dermatitis
  • Psoriasis
  • Actinic keratosis
  • Acne
Newsroom
  1. Home
  2. News & media
  3. Newsroom

Newsroom

Discover the latest news and updates from Almirall.

Quick Links

Almirall press kit

PDF 2.4MB

View Online

Year in review 2024

PDF 2.7MB

View Online

Almirall at a glance

PDF 22.1MB

View Online

Contact us

Corporate Communications
corporate.communication@almirall.com
+34 932 91 35 08

Contact us

Quick links

  • Our Company
  • Our Purpose
  • Our History
  • Sustainability
  • Innovation

I am a...

  • Patient
  • HC Professionals
  • Investors
  • Media

Connect with us

  • Report a side effect
  • Contact
  • Speak Up!

Dermatology

  • Atopic dermatitis
  • Psoriasis
  • Actinic keratosis
  • Acne
  • Onychomycosis
  • Alopecia areata
  • Congenital epidermolysis bullosa

© 2026 Almirall. All rights reserved.

  • Privacy Policy
  • Terms of use
  • Terms and Conditions
  • Cookies
  • Privacy Policy HCPs
  • Accessibility Policy
  • Sitemap

566 results

InvestorsPress release
Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory

Published on 24 July 2026

  • Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution.
  • The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth.
  • Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets.
  • The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM).
  • Almirall advances its innovation strategy through progress across its R&D pipeline, including four ongoing PoC/Phase II studies and two additional PoC studies planned to be initiated by end of 2026, targeting five dermatological diseases. The first readouts are expected towards the end of 2026.
  • Almirall signs a strategic research collaboration and licensing agreement with Certest Biotec to discover and develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.
  • Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA.
cart
R&DPartnering
News
Almirall and Certest Biotec announce research collaboration and licensing agreement

Published on 24 July 2026

Barcelona and San Mateo de Gállego (Zaragoza), Spain.

Almirall, S.A. (ALM) and Certest Biotec, S.L., through its pharmaceutical division Certest Pharma, today announced a strategic research collaboration and licensing agreement. Through the collaboration, the parties will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.


The collaboration combines Certest’s integrated mRNA and Lipid Nanoparticle Platform with Almirall’s expertise in medical dermatology research and clinical development.

“The collaboration with Certest Biotec is aligned with Almirall’s innovation strategy and supports our commitment to advancing a differentiated pipeline and developing novel therapies in medical dermatology that address unmet patient needs,” said Karl Ziegelbauer, Chief Scientific Officer at Almirall.

“This collaboration marks an important milestone for Certest and further validates the strength of our integrated mRNA and lipid nanoparticle platform,” said Nelson Fernandes, CEO of Certest. “Partnering with Almirall allows us to apply our technology to indications with significant unmet medical needs while reinforcing our commitment to enabling the next generation of RNA-based medicines.”
 

CorporatePress release
Almirall announces EMA acceptance for filing of paediatric registration of Ebglyss (lebrikizumab) in atopic dermatitis in children 6 months and older

Published on 20 July 2026

  • The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
  • Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life.
  • As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories.
pride
Corporate
News
Pride Month 2026 with HS Connect

Published on 28 June 2026

As Pride Month comes to a close, we are reminded that the conversation around diversity, inclusion, and belonging should continue every day of the year. At Almirall, we believe that understanding the full patient experience means looking beyond the condition itself and recognizing the unique perspectives and identities that shape each person's journey.


To mark Pride Month, we talked to members of the LGBTQIA+ community who are living with Hidradenitis Suppurativa (HS) and are part of the HS Connect community. Through their personal reflections, Rae Adams, Destineé Spurrel, and Cassandra Stand share their experiences of identity, visibility, and living with a chronic condition. 

Their stories highlight the importance of feeling seen, heard, and respected. They remind us that healthcare goes beyond physical symptoms and that supporting wellbeing requires listening to the diverse experiences of the people we serve.

  
At Almirall, our commitment to medical dermatology is rooted in a holistic approach to care—one that values every individual and fosters greater understanding, empathy, and inclusion. By amplifying patient voices and creating space for meaningful conversations, we can help build a more supportive future for everyone living with skin diseases.

statista
Corporate
News
World's Most Sustainable Companies 2026 by TIME and Statista

Published on 25 June 2026

At Almirall, sustainability is a key part of how we create long-term value for patients, society, and the planet. We are proud to share that we have once again been included in the World’s Most Sustainable Companies 2026 ranking, compiled by TIME and Statista.  


This year, we further strengthened our sustainability performance, improving our overall score from 65.8 to 72.2. This achievement reflects the steady progress we have made in implementing our sustainability strategy and embedding environmental, social, and governance principles across our business.  
 

This recognition highlights the positive momentum of our Act4Impact strategy and the commitment of our teams to advancing responsible and sustainable practices throughout the organization. It also reinforces our belief that business success and sustainable growth go hand in hand.  
 

As we continue our journey, we remain focused on creating a lasting positive impact—driving innovation in medical dermatology while contributing to a healthier and more sustainable future for all.  
 

Thank you to everyone contributing to making sustainability a fundamental part of   who we are and how we operate. 

acne
Patients
News
Acne Awareness Month 2026

Published on 10 June 2026

Acne is one of the most common skin conditions worldwide, affecting millions of people across all ages and backgrounds. Yet, its impact extends far beyond the visible symptoms, often influencing self-confidence, emotional well-being, and daily life.  


During Acne Awareness Month, we want to recognize the profound effect that acne and other dermatological conditions can have on those living with them. Behind every diagnosis is a unique personal journey, reminding us that skin health is about much more than what can be seen on the surface.  


At Almirall, we are committed to advancing medical dermatology and deepening the scientific understanding of skin diseases. Equally important, we believe in listening to the real experiences of patients to help foster a more holistic approach to care—one that considers both physical and emotional wellbeing.  


By increasing awareness and supporting the dermatology community, we aim to contribute to a future where people living with skin conditions feel understood, supported, and empowered throughout their journey.  


Learn more about our commitment to holistic skin health and patient-centered care at:   
https://www.almirall.com/patients
 

environment
Corporate
News
World Environmwent Day: taking climate action today for a better tomorrow

Published on 5 June 2026

At Almirall, improving the lives of patients goes hand in hand with protecting the environment we all share. This World Environment Day, we want to reinforce our commitment to taking decisive climate action on our path to becoming a net-zero emissions company by 2050.

But 2050 is built on the choices we make today. We are already making tangible progress through real, measurable actions. Our operational sites across Spain and Germany have been running on 100% renewable electricity since 2018, and in 2025 we reduced our direct greenhouse gas emissions by 22%, keeping us firmly on track to achieve our 50% reduction target by 2030.

We are also strengthening our approach to water management, having already reduced our consumption by 20% from our baseline, with the ambition to reach a 25% reduction by 2030. These efforts are helping us build greater resilience in the face of climate-related risks.

Our progress has been externally recognised, with Almirall named among Europe’s Climate Leaders 2026 by the Financial Times and Statista for the third consecutive year.

Every action we take brings us one step closer to a more sustainable future — for our patients, our communities and the planet we all share.

hidradenitis
Patients
News
Hidradenitis Suppurativa Awareness Week: making the invisible impact visible

Published on 1 June 2026

During Hidradenitis Suppurativa Awareness Week, we want to shed light on a chronic, painful and often misunderstood condition that goes far beyond the skin. Hidradenitis suppurativa (HS) is a non-contagious inflammatory disease characterized by painful nodules, abscesses and, in some cases, scarring, which can significantly impact patients’ quality of life and daily routines.

Beyond its physical symptoms, HS carries a substantial emotional and psychological burden. Persistent pain, together with stigma and a lack of awareness, can affect sleep, confidence, mental health and overall well-being, often making the invisible impact of the disease as challenging as the visible one. For many people living with HS, managing the condition also means navigating uncertainty and the feeling of not being fully understood.

Raising awareness is essential to improving understanding, encouraging earlier diagnosis and reducing stigma. Greater knowledge of the disease can help patients seek the care they need and support a more timely and accurate diagnosis, while also fostering a more empathetic and informed society.

At Almirall, we remain committed to advancing innovation in medical dermatology and to developing solutions that make a meaningful difference for people living with HS, with a clear focus on addressing both the physical and emotional impact of the disease.

financial time
Corporate
News
Recognised Among Europe’s Climate Leaders by the Financial Times and Statista

Published on 28 May 2026

We’re proud to be recognised for the third consecutive year as one of Europe’s Climate Leaders by the Financial Times and Statista. This recognition reflects the consistent effort we’ve made to turn environmental ambition into tangible results, embedding sustainability into the core of our business.

Over the past years, we have continued to strengthen how we measure and manage our environmental impact, integrating sustainability considerations across decision-making processes, operations, and innovation. This ongoing work allows us not only to track progress more effectively, but also to identify new opportunities to reduce our footprint and contribute positively to the communities and ecosystems we are part of.

Driving real progress means going beyond commitments—it requires measurable action, long-term vision, and continuous improvement. That’s why we remain focused on aligning our corporate strategy with science-based goals, ensuring that every step we take contributes to a more sustainable future.

This milestone is not just about recognition, but about reinforcing our responsibility to keep moving forward.

Skin scouts
Patients
News
AK Global Day: Skin Scouts — Observe, Detect, Act

Published on 24 May 2026

On AK Global Day, we launched Skin Scouts, a global awareness initiative designed to reinforce the importance of early detection in medical dermatology. The campaign encourages everyone to look closer at their skin and recognize early warning signs that often go unnoticed, helping transform awareness into timely and meaningful action.

Actinic keratosis is a common condition that can act as an early warning sign of skin cancer. Too often, these lesions are mistaken for harmless skin changes linked to ageing or sun exposure. That is why, on AK Global Day, we proudly launch the #AKSkinScouts initiative to remind people that paying attention early can make a critical difference for long-term skin health.

Built around three simple steps — observe, detect, and act — Skin Scouts aims to empower the general public with practical knowledge. The campaign encourages regular skin observation, greater awareness of rough or scaly patches in sun-exposed areas, and a better understanding of key risk factors such as chronic sun exposure and skin type.

By combining education, awareness, and a clear call to action, Skin Scouts promotes a proactive approach to skin health and shared responsibility. Through engaging content and simple gestures, the initiative invites everyone to sharpen their focus, join the movement, and help spread a message that can lead to earlier detection and better outcomes.

12357Next
News type